A Study to Evaluate AuTophagy Activation for Cardiomyopathy Due to Anthracycline tReatment


About this study

The purpose of this study is to evaluate the additional benefit of pravastatin and spironolactone when given in combination with carvedilol and lisinopril versus carvedilol and lisinopril alone.


Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion criteria:

- ≥ 18 years of age,

- New diagnosis of reduced cardiac function

- Prior anthracycline-based cancer therapy for lymphoma

Exclusion criteria:

- History of HF of any class and type, or diagnosis of cardiomyopathy prior to
anthracycline therapy

- On active therapy with a fibrate, niacin, or eplerenone

- History of myopathy/rhabdomyolysis

- History of statin intolerance

- Active hyperlipidemia

- History of gout

- Active liver disease

- Unexplained persistent elevations of serum transaminases

- Pregnancy

- Breast-feeding

- Hyperkalemia

- Addison disease

- eGFR <30 mL/minute/1.73 m^2

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 12/8/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Joerg Herrmann, M.D.

Open for enrollment

Contact information:

Tiffany Hansen

(507) 293-0196


More information


Publications are currently not available

Mayo Clinic Footer